The pathophysiology of ventricular arrhythmia: does inflammation increase the risk of ventricular arrhythmia through hyperthermia and/or inflammatory cytokines?

The pathophysiology of ventricular arrhythmia: does inflammation increase the risk of ventricular arrhythmia through hyperthermia and/or inflammatory cytokines? - The role of inflammation in the pathophysiology of ventricular arrhythmia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32785

Enrollment

200

Registered

2008-12-15

Start date

2008-11-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ventricular arrhythmia ventricular fibrillation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult patients, who are eligible for the emplacement of an implantable cardioverter defibrillator (ICD) according to current guidelines (group 1); and adult patient with an ICD, who present after an episode of VT/VF and/or ICD discharge (group 2).

Exclusion criteria

Exclusion criteria: Patients using anti-pyretic or anti-inflammatory drugs.

Design outcomes

Primary

Measure	Time frame
Proportion of VT/VF and/or ICD discharge episodes that occur during hyperthermia (body temperature >37.5°), and serum levels of interleukin-6, interleukin-8 and CRP during each episode of VT/VF and/or ICD discharge.	—

Secondary

Measure	Time frame
1. Proportion of patients with ECG changes during hyperthermia or when serum levels of interleukin-6, interleukin-8 and/or CRP are increased. 2. Changes in body temperature and serum levels of interleukin-6, interleukin-8 and CRP that occurs during each episode of VT/VF and/or ICD discharge. 3. Clinical variables (e.g., ischemia, heart failure, electrolyte imbalance, drug use) and cytokine gene variables that may determine the occurrence of VT/VF during inflammation.	—

Measure

Time frame

1. Proportion of patients with ECG changes during hyperthermia or when serum levels of interleukin-6, interleukin-8 and/or CRP are increased. 2. Changes in body temperature and serum levels of interleukin-6, interleukin-8 and CRP that occurs during each episode of VT/VF and/or ICD discharge. 3. Clinical variables (e.g., ischemia, heart failure, electrolyte imbalance, drug use) and cytokine gene variables that may determine the occurrence of VT/VF during inflammation.

—

Countries

Netherlands

Outcome results